Profil bibliographique

Elham Vosoughi

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

26Publications signalées

229Citations signalées

2Affiliations récentes

Les institutions déclarées

University of California, San Francisco Collaborative Drug Discovery (United States)

Les domaines associés

Melanoma and MAPK PathwaysCutaneous Melanoma Detection and ManagementBreast Cancer Treatment StudiesCancer Immunotherapy and BiomarkersRenal cell carcinoma treatment

Les publications récentes

2026 conference-abstract OpenAlex

Abstract PS4-08-26: Weekly carboplatin and paclitaxel with trastuzumab and pertuzumab (HER2+) or bevacizumab (HER2-) in the neoadjuvant treatment of breast cancer: a phase II trial

Farah Shah, S. Gibson, F. Luo, M. Thomas et autres

us (code pays fourni par la source)

0 citations Clinical Cancer Research

Accès ouvert 2025 article OpenAlex

Understanding Patient and Oncologist Preferences in the Management of Metastatic Renal Cell Carcinoma

Omid Yazdanpanah, A. Mahadevan, David J. Benjamin, Elham Vosoughi et autres

us (code pays fourni par la source)

0 citations Cancer Treatment and Research Communications

Accès ouvert 2025 article OpenAlex

Real-world Monitoring of ctDNA Reliably Predicts Cancer Recurrence and Treatment Efficacy in Patients with Resected Stages I-III Colon Cancer

Stacey A. Cohen, Vasily N. Aushev, George Laliotis, Iktej Singh Jabbal et autres

us (code pays fourni par la source)

8 citations Annals of Surgery

2024 conference-abstract OpenAlex

Mutational landscape of HER-2 low breast cancer.

Elham Vosoughi, Nellie Nafissi, A. Mahadevan, Seungshin Lee et autres

us (code pays fourni par la source)

0 citations Journal of Clinical Oncology

Accès ouvert 2024 conference-abstract OpenAlex

Understanding patient and provider preferences in management of metastatic renal cell carcinoma (mRCC).

Omid Yazdanpanah, David J. Benjamin, Elham Vosoughi, Ali Raad et autres

us (code pays fourni par la source)

0 citations Journal of Clinical Oncology

Accès ouvert 2023 conference-abstract OpenAlex

Immune related adverse events (irAEs) in patients with solid tumors and advanced chronic kidney disease (CKD) receiving checkpoint inhibitors (CPIs).

Dalia Kaakour, Elham Vosoughi, Brian Warnecke, Omid Yazdanpanah et autres

us (code pays fourni par la source)

0 citations Journal of Clinical Oncology

2023 conference-abstract OpenAlex

Real-life experience of trastuzumab deruxtecan (T-DXd) in patients with heavily pretreated HER2 positive advanced breast cancer: A retrospective single institution study.

Elham Vosoughi, Nellie Nafissi, A. Mahadevan, Seungshin Lee et autres

us, np (code pays fourni par la source)

4 citations Journal of Clinical Oncology

Accès ouvert 2023 conference-abstract OpenAlex

A phase II study of weekly carboplatin and nab-paclitaxel with trastuzumab or bevacizumab as neoadjuvant therapy for patients with early-stage nonmetastatic breast cancer.

Elham Vosoughi, Nellie Nafissi, A. Mahadevan, Seungshin Lee et autres

us, np (code pays fourni par la source)

0 citations Journal of Clinical Oncology

2023 conference-abstract OpenAlex

Safety and tolerability of immune checkpoint inhibitor (CPI) use in advanced hepatocellular carcinoma (aHCC) with Child-Pugh (CP) class B and C.

Jennifer Brooke Valerin, Dalia Kaakour, Nataliya Mar, Elham Vosoughi

us (code pays fourni par la source)

0 citations Journal of Clinical Oncology

Accès ouvert 2023 supplementary-materials OpenAlex

Supplementary Data from Role of Elevated PHIP Copy Number as a Prognostic and Progression Marker for Cutaneous Melanoma

Vladimir Bezrookove, Mehdi Nosrati, James R. Miller, David de Semir et autres

0 citations

Accès ouvert 2023 other OpenAlex

Data from Role of Elevated PHIP Copy Number as a Prognostic and Progression Marker for Cutaneous Melanoma

Vladimir Bezrookove, Mehdi Nosrati, James R. Miller, David de Semir et autres

0 citations

Accès ouvert 2023 supplementary-materials OpenAlex

Supplementary Data from Role of Elevated PHIP Copy Number as a Prognostic and Progression Marker for Cutaneous Melanoma

Vladimir Bezrookove, Mehdi Nosrati, James R. Miller, David de Semir et autres

0 citations

Profil ORCID Notice OpenAlex

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.